NEW YORK, March 3, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SCYNEXIS, Inc. ("SCYNEXIS" or the "Company") (NASDAQ: SCYX). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. 9980.
The investigation concerns whether SCYNEXIS and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On March 2, 2017, post-market, Scynexis announced that the U.S. Food and Drug Administration ("FDA") has placed a clinical hold on clinical trials for the intravenous formulation of the Company's lead product candidate SCY-078, "until the FDA completes a review of all available pre-clinical and clinical data." Scynexis advised investors that "[t]he clinical hold decision was issued by the FDA following a review of three mild-to-moderate thrombotic events in healthy volunteers receiving the IV formulation of SCY-078 at the highest doses and highest concentrations in a Phase 1 study."
On this news, Scynexis's share price has fallen as much as $0.67, or 20.49%, during intraday trading on March 3, 2017.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
Robert S. Willoughby
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-scynexis-inc--scyx-300417760.html
SOURCE Pomerantz LLP